drugset / Trial / NCT02381470
Trial of Faropenem and Cefadroxil (in Combination With Amoxicillin/Clavulanic Acid and Standard TB Drugs) in Patients With Pulmonary Tuberculosis: Measurement of Early Bactericidal Activity and Effects on Novel Biomarkers
RandomizedParallel-groupSingle-blindTreatment
Summary
This trial aims to determine whether the early bactericidal activity of rifampicin given with faropenem or cefadroxil (each given with amoxicillin/clavulanic acid) is greater than the activity of rifampicin alone in patients with pulmonary TB. The trial will also investigate potential new biomarkers of sterilising activity.
Timeline
- Start
- 2019-02-11
- Primary completion
- 2019-09-28
- Completion
- 2019-10-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Amoxicillin | Other / unclassified | 500 mg | — |
| Subject | Cefadroxil | Small molecule | 1 g | Oral |
| Subject | Faropenem | Small molecule | 600 mg | Oral |
| Subject | clavulanic acid | Small molecule | 125 mg | — |
| Comparator | Rifampin | Small molecule | 10 mg/kg | — |